Study to Assess PK, Safety and Tolerability in Healthy Subjects - Trial NCT06380699
Access comprehensive clinical trial information for NCT06380699 through Pure Global AI's free database. This Phase 1 trial is sponsored by Changzhou Qianhong Bio-pharma Co., Ltd. and is currently Completed. The study focuses on Acute Ischemic Stroke. Target enrollment is 56 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Changzhou Qianhong Bio-pharma Co., Ltd.
Timeline & Enrollment
Phase 1
Mar 16, 2023
Dec 25, 2023
Primary Outcome
Safety as assessed by incidence, severity, and causality of adverse events,Plasma measurements of QHRD106,Concentration of bradykinin in plasma
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and
 pharmacodynamics (PD) of QHRD106 in Chinese healthy subjects with single and multiple doses.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06380699
Non-Device Trial